Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.

MLA

Cortese, Brian D., et al. “Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 41, no. 29, Oct. 2023, pp. 4664–68. EBSCOhost, https://doi.org/10.1200/JCO.23.00079.

APA

Cortese, B. D., Dusetzina, S. B., Luckenbaugh, A. N., Al Hussein Al Awamlh, B., Stimson, C. J., Barocas, D. A., Penson, D. F., Chang, S. S., & Talwar, R. (2023). Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 41(29), 4664–4668. https://doi.org/10.1200/JCO.23.00079

Chicago

Cortese, Brian D, Stacie B Dusetzina, Amy N Luckenbaugh, Bashir Al Hussein Al Awamlh, C J Stimson, Daniel A Barocas, David F Penson, Sam S Chang, and Ruchika Talwar. 2023. “Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 41 (29): 4664–68. doi:10.1200/JCO.23.00079.